BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AK146D1 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AK146D1\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07669779-2336@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:AK146D1: Phase 2 readout est. (NCT07669779)
DESCRIPTION:AK146D1\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase
  II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 30 August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ak146d1#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/ak146d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591090-2336@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:AK146D1: Phase 2 readout est. (NCT07591090)
DESCRIPTION:AK146D1\, phase 2.\nStudy: A Phase II Study of AK146D1 Combined
  With AK112 in Advanced Breast Cancer\nEstimated primary completion: 1 Sep
 tember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ak146d1#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0759
 1090
URL:https://assetmemo.bio/drug/ak146d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929663-2336@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:AK146D1: Phase 1 readout est. (NCT06929663)
DESCRIPTION:AK146D1\, phase 1.\nStudy: A Study of AK146D1 as Monotherapy an
 d in Combination With AK104 or AK112\, in the Treatment of Advanced Solid 
 Tumors\nEstimated primary completion: 30 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ak146d1#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06929663
URL:https://assetmemo.bio/drug/ak146d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636772-2336@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280824
DTEND;VALUE=DATE:20280825
SUMMARY:AK146D1: Phase 2 readout est. (NCT07636772)
DESCRIPTION:AK146D1\, phase 2.\nStudy: A Phase II Study of AK146D1 Mono or 
 Combined With AK112 in Advanced Urothelial Carcinoma\nEstimated primary co
 mpletion: 24 August 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ak146d1#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07636772
URL:https://assetmemo.bio/drug/ak146d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
